The Korean Journal of Nuclear Medicine (대한핵의학회지)

The Korean Society of Nuclear Medicine (대한핵의학회)
권호 표지

The Role of PET in Lung Cancer

폐암에서 PET의 역할

  • Kim, Byung-Tae (Department of Nuclear Medicine, Samsung Medical Center Sungkyunkwan University School of Medicine)
  • 김병태 (성균관대학교 의과대학 삼성서울병원 핵의학과)
  • Published : 2002.02.28
Download PDF
⟨ Previous Next ⟩

Abstract

Lung cancer has become a loading cause of cancer death in Korea. Positron emission tomography was introduced in clinical nuclear medicine in the early 1990s and many studios using this functional imaging technology were performed for evaluation of its clinical utility. I review the current role of positron emission tomography in the diagnosis, staging, and therapy monitoring of lung cancer.

Keywords

References

  1. Ahuja v, Coleman RE, Herndon J, Patz EF Jr. Theprognostic significance of fluorodeoxyglucose positronemission tomography imaging for patients withnonsrnall cell lung carcinoma. Cancer 1998;83:918-924
  2. Crotty E, Patz EF. FDG-PET imaging in patientswith paraneoplastic syndrome and suspected smallcell lung cancer. J Thorae Imaging 2001;16:89-93.
  3. Dewan NA, Reeb SD, Gupta NC, Gobar LS, ScottWl PET-FDG imaging and transthoracic needlelung aspiration biopsy in evaluation of pulmonarylesions: A comparative risk-benefit analysis. Chest1995;108:441-446.
  4. Duhaylongsod FG, Lowe VJ, Pstz EF Jr, VaughnAL, Coleman RE, Wolfe WG. Lung tumor growthcorrelates with glucose metabolism ..measured byfluoride-18 fluorodeoxyglucose positron emissiontomography. Ann Thorae Surg 1995;60:1348-1352.
  5. Dwamena BA, Sonnad SS, Angobaldo JO, WahlRL. Metastases from non-small cell lung cancer:Mediastinal staging in the 1990s - Meta-analyticcomparison of PET and CT. Radiology 1999;213:530-536.
  6. Erasmus JJ, Patz EF Jr, McAdams HP, Murray JG,Herndon J, Coleman RE, et al. Evaluation ofadrenal masses in patients with bronchogeniccarcinoma using 18F-fluorodeoxyglucose positronemission tomography. AJR 1997;168:1357-1360.
  7. Gambhir SS, Hoh CK, Phelps ME, Madar I,Maddahi J. Decision tree sensitivity analysis forcost-effectiveness of FDG-PET in the staging andmanagement of non-small-cell lung carcinoma. JNucl Med 1996;37:1428-1436.
  8. Gdeedo A, Van Schill P, Corthouls B, VanMieghem F, Van Meerbeeck J, Van Marek E.Prospective evaluation of computed tomography andmediastinoscopy in mediastinal lymph node staging.Eur Respir J 1997;10:1547-1551.
  9. Gould MK, Maclean CC, Kuschner WG, RydzakCE, Owens DK. Accuracy of positron emissiontomography for diagnosis of pulmonary nodules andmass lesions. JAMA 2001;285:914-924.
  10. Ichiya Y, Kuwabara Y, Otsuka M, Tahara T,Yoshikai T, Fukumura T, et al. Assessment ofresponse to cancer therapy using fluorine-18fluorodeoxyglucoseand positron emissiontomogrphy. J Nucl Med 1991;32:1655-1660.
  11. Inoue T, Kim EE, Komaki R, Wong FC, Bassa P,Wong WH, et al. Detecting recurrent or residuallung cancer with FDG-PET. J Nucl Med 1995;36:788-793.
  12. Kim B-T, Kim Y, Lee KS, Yoon SB, Cheon EM,Kwon OJ, et al. Localized form of bronchioloalveolarcarcinoma: FDG PET findings. AJR 1998;170:935-939.
  13. Laking G, Price P. l S-Fluorodeoxyglucose positronemission tomography (FDG-PET) and the staging ofearly lung cancer. Thorax 2001;56(Suppl II):ii38-ii44.
  14. Lee JD, Ginsberg RJ. Lung cancer staging: Thevalue of ipsilateral scalene lymph node biopsyperformed at mediastinoscopy. Ann Thore Surg1996;62:338-341.
  15. Lewis P, Griffin S, Marsden P, Gee T, Nunan T,Malsey M, et al. Whole-body 18F-fluorodeoxyglucosepositron emission tomography in preoperativeevaluation of lung cancer. Lancet 1994;344:1265-1266.
  16. Lowe VJ, Duhaylongsod FG, Patz EF, Delong DM,Hoffman JM, Wolfe WG, et al. Pulmonaryabnormalities and PET data analysis aretrospective study. Radiology 1997;202:435-439.
  17. Lowe VJ, Fletcher JW, Gobar L, Lawson M,Kirchner P, Valk P, et al. Prospective investigationof positron emission tomography in lung nodules. JClin Oneol 1998;16:1075-1084.
  18. Marom EM, McAdams HP, Erasmus JJ, GoodmanPC, Culhane DK, Coleman RE, et al. Stagingnon-small cell lung cancer with whole-body PET.Radiology 1999;212:803-809.
  19. Schumacher T, Brink I, Mix M, Reinhardt M,Herget G, Digel W, et al. FDG-PET imaging forthe staging and follow-up of small cell lung cancer.Eur J Nucl Med 2001;28:483-488.
  20. Shields AF, Mankoff DA, Link JM, Graham MM,Eary JF, Kozawa SM, et al. Carbon-ll-thymidineand FDG to measure therapy response. J Nucl Med1998;39:1757-1762.
  21. Valk PE, Pounds TR, Hopkins DM, Haseman MK,Hofer GA, Greiss HB, et al. Staging non-small celllung cancer by whole-body positron emissiontomographic imaging. Ann Thome Surg 1995;60:1573-1582.
  22. Whittlesey D. Prospective computed tomographicscanning in the staging of bronchogenic cancer. JThome Cardiovasc Surg 1988;95:876-882.
  23. Wong CO, Nunez R, Bohdiewicz P, Welsh RJ,Chmielewski GW, Ravikrishnan KP, et al. Patternsof abnormal FDG uptake by various histologicaltypes of non-small cell lung cancer at initial stagingby PET. Eur J Nucl Med 2001;28:1702-1705.
  24. Yoon SB, Kim B-T, Choi JY, Kim SJ, Choi Y,Choe YS, et al. Role of PET in evaluatingindeterminate solitary pulmonary nodule with CT.Korean J Nucl Med 1997;31:83-89.
  25. Younes M, Brown RW, Stephenson M, Gondo M,Cagle PT. Overexpression of Glut! and Glut3 instage 1 nonsmall cell lung carcinoma is associatedwith poor survival. Cancer 1997;80:1046-1051.